Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. company information, Employees & Contact Information

Catalyst Pharmaceuticals, Inc., (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies. For more information, please visit Catalyst's website at www.catalystpharma.com. View our Privacy Policy: https://catalystpharma.com/privacy-policy/ View our Social Media Guidelines: https://catalystpharma.com/social-media-guidelines/

Company Details

Employees
181
Founded
-
Address
355 Alhambra Circle,
Phone
3055290933
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Coral Gables, Florida
Looking for a particular Catalyst Pharmaceuticals, Inc. employee's phone or email?

Catalyst Pharmaceuticals, Inc. Questions

News

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 GlobeNewswire

Catalyst Pharmaceuticals (NASDAQ: CPRX) sets results call for Nov 6 at 8:30 AM ET - Stock Titan

Catalyst Pharmaceuticals (NASDAQ: CPRX) sets results call for Nov 6 at 8:30 AM ET Stock Titan

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program - GlobeNewswire

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program GlobeNewswire

$200M Share Buyback: Catalyst Pharmaceuticals Taps Into $650M Cash Reserve for Stockholder Returns - Stock Titan

$200M Share Buyback: Catalyst Pharmaceuticals Taps Into $650M Cash Reserve for Stockholder Returns Stock Titan

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update - Yahoo Finance

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update Yahoo Finance

Rare Disease Leader Catalyst Pharmaceuticals Sets Four Major Healthcare Conference Appearances in September - Stock Titan

Rare Disease Leader Catalyst Pharmaceuticals Sets Four Major Healthcare Conference Appearances in September Stock Titan

Catalyst Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 - Quiver Quantitative

Catalyst Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 Quiver Quantitative

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire

12-Year Patent Protection: Catalyst Pharma Locks FIRDAPSE Exclusivity Until 2035 in Lupin Settlement - Stock Titan

12-Year Patent Protection: Catalyst Pharma Locks FIRDAPSE Exclusivity Until 2035 in Lupin Settlement Stock Titan

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals - Yahoo Finance

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals Yahoo Finance

Rare Disease Drug FIRDAPSE Protected Until 2035: Catalyst Pharma Wins Patent Settlement with Lupin - Stock Titan

Rare Disease Drug FIRDAPSE Protected Until 2035: Catalyst Pharma Wins Patent Settlement with Lupin Stock Titan

Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals - GlobeNewswire

Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals GlobeNewswire

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - Stock Titan

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 Stock Titan

Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan

Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth Stock Titan

Catalyst Pharmaceuticals Enters Into an Exclusive License, - GlobeNewswire

Catalyst Pharmaceuticals Enters Into an Exclusive License, GlobeNewswire

Top Catalyst Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant